Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 21:32 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Digoxin for Congenital Erythrocytosis Due to Up-Regulated Hypoxia Sensing
NCT03433833 · University of Illinois Chicago · PHASE1 · withdrawn · last registry update 2024-09-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study Not Funded” | – | Registry record, University of Illinois Chicago |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ATP1A1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-07-02Results posted on the registry: University of Maryland, Baltimore, Digoxin Antibodies Fab Fragments (NCT03810417)
- 2025-04-22Also stopped (withdrawn): ViiV Healthcare, Part A, C and D: VH3739937 500 mg + Part A: VH3739937 100 mg (NCT06533280)
- 2025-04-01Also stopped (withdrawn): Turning Point Therapeutics, Inc., TPX-0005 + Metformin Hydrochloride (NCT05828303)
- 2025-02-21Results posted on the registry: Eli Lilly and Company, Pirtobrutinib + Digoxin (NCT06194214)
- 2025-02-20Also stopped (terminated): Damascus University, mono nuclear cells injection + Digoxin+furosemide+captopril (NCT04893629)
- 2024-12-27Results posted on the registry: Corewell Health South, Oral + Intravenous drug (NCT05391893)
- 2024-10-08Results posted on the registry: Global Alliance for TB Drug Development, TBAJ-876 + Midazolam (NCT05526911)
- 2024-07-12Results posted on the registry: Yale University, Digoxin + Digoxin (NCT03559868)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision